Preview

FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology

Advanced search

PHA RMA COE CONOMI CAL EVALUATION OF MULTIPLE MYELOMA TREATMENT WITH REVLIMID (LENALIDOMIDE ) IN THE RUSSIAN FEDE RATION

Abstract

Pharmacoeconomic evaluation of treatment of the second and third lines of multiple myeloma with Revlimid in Russia was conducted. It has shown, that application of lenalidomide as a drug of choice in the treatment of multiple myeloma in second-line therapy and is preferable from the perspective of the health economics.

About the Authors

R. Yagudina
The First MSMU named after I.M. Sechenov
Russian Federation
Laboratory of pharmacoeconomical research


A. Kulikov
The First MSMU named after I.M. Sechenov
Russian Federation
Laboratory of pharmacoeconomical research


B. Misikova
The First MSMU named after I.M. Sechenov
Russian Federation
Laboratory of pharmacoeconomical research


References

1. Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol. 1998; 102:1115-23.

2. Boyle P, Ferlay J.Cancer incidence and mortality in Europe, 2004. Ann Oncol. 2005;16:481-8.

3. Dimopoulos M, Spencer A, Attal M, Miles Prince H, Harousseau J-Let al. Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2007;357(21):2123-32.

4. Greipp PR, San Miguel J, Durie BGM, Crowley JJ, Barlogie B, Blade J, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23:3412-20.

5. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106-30.

6. Kuehl WM, Bergsagel PL. Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer. 2002;2:175-87.

7. Kyle RA, Gertz MA, Witzig ТЕ, Lust JA, Lacy MQ, Dispenzieri A, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc.2003;78:21-33.

8. Richardson PG, Sonneveld P, Schuster MW, et al. Extended followup of a phase 3 trial in relapsed multiple myeloma: Final time-toevent results of the APEX trial. Blood. 2007; 110(10):3557-60.

9. Sant M, Aareleid T, Berrino F, Bielska Lasota M, Carli PM, Faivre J, et al. EUROCARE-3: survival of cancer patients diagnosed 1990-94-results and commentary. Ann Oncol. 2003; 14 Suppl 5:v61-v118.

10. Stadtmauer et al. Lenalidomide in combination with dexamethasone is more effective than dexamethasone at first relapse in multiple myeloma. Abstract #3552, ASH 2006.

11. Weber D, Knight R, Chen C, Spencer A, et al. Prolonged overall survival with lenalidomide plus dexamethasone compared with dexamethasone alone in patients with relapsed or refractory multiple myeloma. Abstract #412, ASH 2007.

12. Weber DM, Chen C, Niesvizky R, Wang M, Belch A. et al. Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America; N Engl J Med. 2007;357(21):2133-42.

13. Информационный ресурс www.aptechka.ru [по состоянию на 05.09.2010]

14. Прайс-лист ММА им. И. М. Сеченова www.mma.ru

15. Прейскурант Онкологического центра им. Н. Н. Блохина.

16. Приказ Минздравсоцразвития РФ от 21.07.2006 n 549 об утверждении стандарта медицинской помощи больным множественной миеломой.

17. Регистр предельных отпускных цен производителей по состоянию на 15.04.10.


For citation:


Yagudina R., Kulikov A., Misikova B. PHA RMA COE CONOMI CAL EVALUATION OF MULTIPLE MYELOMA TREATMENT WITH REVLIMID (LENALIDOMIDE ) IN THE RUSSIAN FEDE RATION. FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology. 2012;5(1):13-19.

Views: 379


ISSN 2070-4909 (Print)
ISSN 2070-4933 (Online)